Medical device company ResMed (NYSE: RMD) beat Wall Street’s revenue expectations in calendar Q3 2026 (fiscal Q1 2027), with sales up 5.9% year on year to $1.41 billion. Its non-GAAP profit of $2.91 per share was 8.9% above analysts’ consensus estimates.

Is now the time to buy RMD? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

ResMed’s third quarter was marked by steady revenue growth and a modestly positive market reaction, as sales and non-GAAP earnings per share surpassed Wall Street expectations. Management attributed the quarter’s performance to productivity gains across procurement and manufacturing, the rapid launch of new products, and operational improvements in its U.S. and global supply chain. CEO Mick Farrell emphasized that the transition to advanced devices like the AirCurve 11 and expansion of digital health tools contributed to higher therapy adherence and patient engagement. Notably, the company also benefited from favorable product mix and efficiency measures, which helped offset ongoing inflationary pressures and softer contributions from price increases, which are expected to build later in the year.

Looking forward, ResMed’s outlook is shaped by ongoing investment in product development, digital health ecosystem expansion, and targeted marketing initiatives aimed at driving durable growth. Management is focused on leveraging partnerships with consumer technology and pharmaceutical companies to broaden the sleep health funnel and improve therapy adherence rates. CFO Aaron Bloomer highlighted that the company’s forward guidance incorporates expectations for continued inflation, supply chain investments, and evolving demand patterns, stating, “We are laser focused on achieving operating leverage by driving productivity and efficiency.” The company remains attentive to the timing of price realization, the impact of new marketing campaigns, and the normalization of demand following sizable fleet renewals in international markets.

Key insights from management’s remarks

Management attributed the quarter’s results to operational improvements in manufacturing, continued product launches, and early returns from digital health investments, while noting product mix and strategic divestitures affected segment performance.

• Product innovation drives engagement: The launch of the AirCurve 11 ST and ST-A bilevel devices and the AirTouch F40 fabric mask targeted more complex sleep and breathing disorders, supporting therapy adherence and broadening ResMed’s market reach.
• Digital health ecosystem expands: Updates to the myAir app, including new AI-powered coaching and equipment care features, drove patient engagement, with more than 13 million downloads and a marked increase in therapy compliance rates among users.
• Operational excellence in supply chain: Accelerated expansion of U.S. manufacturing, notably the first made-in-America CPAP device, and progress on the new Indiana distribution center, provided flexibility and efficiency while mitigating risks from global supply chain disruptions.
• Portfolio optimization: The divestiture of MatrixCare and integration of Nidra (restless legs syndrome therapy) shifted focus to higher-growth, higher-margin segments, with early traction seen in Brightree and MEDIFOX DAN.
• Marketing and awareness initiatives: New campaigns and partnerships with consumer tech and pharma companies, such as ŌURA and Eight Sleep, are designed to increase awareness and funnel new patients into diagnosis and therapy, though material benefit to revenue is expected over a longer horizon.

Drivers of future performance

ResMed’s outlook centers on sustained product innovation, digital ecosystem expansion, and targeted marketing, balanced by inflationary pressures and evolving demand in key markets.

• Digital and AI-driven patient support: Management expects continued adoption of digital tools, such as the enhanced myAir app and AI-powered sleep coaching, to boost patient adherence and drive resupply activity, supporting both revenue growth and improved therapy outcomes.
• Marketing and partnerships: The company is prioritizing marketing campaigns and collaborations with consumer tech and pharma partners to expand the sleep health funnel, with success here likely to determine whether growth trends toward the upper end of guidance.
• Inflation and international demand normalization: Persistent inflation, especially in electronic components, and the anticipated tapering of international device demand following the France fleet renewal are expected to pose headwinds, though ongoing operational improvements and pricing initiatives may help offset these factors.

Catalysts in upcoming quarters

In upcoming quarters, our analysts will be monitoring (1) the measurable impact of new product launches and digital health tools on therapy adherence and resupply rates, (2) the pace and efficiency of U.S. manufacturing expansion and supply chain optimization, and (3) the effectiveness of marketing campaigns and partnerships in driving new patient growth. Additionally, we will track the normalization of international demand following large fleet renewal cycles and ongoing inflation’s impact on margins.

ResMed currently trades at $235.00, down from $252.83 just before the earnings. Is there an opportunity in the stock? The answer lies in our full research report (it’s free).

Our favorite stocks right now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.